/EKTA-B.ST

EKTA-B.ST Stock - Elekta AB (publ)

Q: What is the analyst price target for EKTA-B.ST?

Analyst price target information is not currently available for EKTA-B.ST.

Q: What is EKTA-B.ST's market cap?

Market capitalization information is not currently available for EKTA-B.ST.

Healthcare|Medical - Instruments & Supplies|STO

$56.20+0.18%

+$0.10 (+0.18%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $61.82

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for EKTA-B.ST

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.06

52W High$67.65

52W Low$40.64

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$18.02B	$18.12B	$16.87B	$14.55B	$13.76B
Gross Profit	$6.75B	$6.80B	$6.35B	$5.44B	$5.61B
Gross Margin	37.4%	37.5%	37.6%	37.4%	40.8%
Operating Income	$890.00M	$2.04B	$1.43B	$1.64B	$1.91B
Net Income	$237.00M	$1.30B	$943.00M	$1.15B	$1.25B
Net Margin	1.3%	7.2%	5.6%	7.9%	9.1%
EPS	$0.62	$3.41	$2.47	$3.02	$3.28

Company Overview

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Visit Website

Earnings History & Surprises

EKTA-B.ST

Beat Rate

44%

Last 18 quarters

Avg Surprise

-5.8%

EPS vs Estimate

Beats / Misses

8/9

1 met exactly

Latest EPS

$0.63

Q4 2025

EPS Surprise History

Q1 24

-14.9%

$0.80vs$0.94

Q2 24

-22.3%

$1.15vs$1.48

Q3 24

+20.6%

$0.41vs$0.34

Q4 24

-27.8%

$0.64vs$0.89

Q1 25

-10.5%

$0.94vs$1.05

Q2 25

-24.0%

$1.11vs$1.46

Q3 25

-58.3%

$0.28vs$0.67

Q4 25

+4.8%

$0.63vs$0.60

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 28, 2026	—	—	—	—
Q1 2026	Mar 5, 2026	—	—	—	—
Q4 2025	Nov 25, 2025	$0.60	$0.63	+4.8%	✓ BEAT
Q3 2025	Aug 28, 2025	$0.67	$0.28	-58.3%	✗ MISS
Q2 2025	May 28, 2025	$1.46	$1.11	-24.0%	✗ MISS
Q1 2025	Feb 21, 2025	$1.05	$0.94	-10.5%	✗ MISS
Q4 2024	Nov 27, 2024	$0.89	$0.64	-27.8%	✗ MISS
Q3 2024	Aug 28, 2024	$0.34	$0.41	+20.6%	✓ BEAT
Q2 2024	Jun 5, 2024	$1.48	$1.15	-22.3%	✗ MISS
Q1 2024	Feb 29, 2024	$0.94	$0.80	-14.9%	✗ MISS
Q4 2023	Nov 30, 2023	$0.94	$0.94	0.0%	= MET
Q3 2023	Aug 24, 2023	$0.43	$0.65	+51.2%	✓ BEAT
Q2 2023	May 25, 2023	$1.24	$1.53	+23.4%	✓ BEAT
Q1 2023	Feb 24, 2023	$0.67	$0.83	+23.9%	✓ BEAT
Q4 2022	Nov 24, 2022	$0.53	$0.55	+3.8%	✓ BEAT
Q3 2022	Aug 25, 2022	$0.58	$0.16	-72.4%	✗ MISS
Q2 2022	May 25, 2022	$0.87	$1.09	+25.3%	✓ BEAT
Q1 2022	Feb 24, 2022	$0.68	$0.60	-11.8%	✗ MISS
Q4 2021	Nov 25, 2021	$0.76	$1.00	+31.6%	✓ BEAT
Q3 2021	Aug 25, 2021	$0.63	$0.33	-47.6%	✗ MISS

Frequently Asked Questions about EKTA-B.ST

What is EKTA-B.ST's current stock price?

Elekta AB (publ) (EKTA-B.ST) is currently trading at $56.20 per share. The stock has moved +0.18% today.

What is the analyst price target for EKTA-B.ST?

No analyst price targets are currently available for this stock.

What sector is Elekta AB (publ) in?

Elekta AB (publ) operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the STO exchange.

What is EKTA-B.ST's market cap?

Elekta AB (publ) has a market capitalization of $20.63 billion, making it a large-cap company.

Does EKTA-B.ST pay dividends?

No, Elekta AB (publ) does not currently pay a dividend to shareholders.